Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | GPX4 | P36969 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202738 | 0.86 | IRAK4 (0.41) | NAMPTIRAK4NTRK1ALDH1A1MAPT | |
| SCHEMBL1203652 | 0.85 | MEN1 (0.43) | TDP1GPX4MEN1ALDH1A1LMNA | |
| SCHEMBL2900291 | 0.83 | TIPARP (0.41) | NAMPTTDP1IRAK4ROCK2ALDH1A1 | |
| SCHEMBL1203223 | 0.82 | KMT2A (0.46) | TDP1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1203002 | 0.78 | PTPN11 (0.44) | IRAK4NTRK1ALDH1A1MAPT | |
| SCHEMBL1203613 | 0.77 | CLK1 (0.48) | CLK1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1202888 | 0.76 | FYN (0.39) | NAMPTIRAK4NTRK1 | |
| SCHEMBL1203328 | 0.73 | FYN (0.55) | CLK1NTRK1HIF1A | |
| SCHEMBL1203562 | 0.72 | MAPT (0.41) | MEN1LMNAMAPTKMT2A | |
| SCHEMBL1203496 | 0.72 | PTPN11 (0.53) | IRAK4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | CLK1 792/4885NAMPT 3511/4885TDP1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.